Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuraxis (NRXS) Common Equity (2022 - 2025)

Neuraxis' Common Equity history spans 4 years, with the latest figure at $2.3 million for Q3 2025.

  • For Q3 2025, Common Equity rose 227.37% year-over-year to $2.3 million; the TTM value through Sep 2025 reached $2.3 million, up 227.37%, while the annual FY2024 figure was $2.1 million, 247.36% up from the prior year.
  • Common Equity for Q3 2025 was $2.3 million at Neuraxis, down from $4.3 million in the prior quarter.
  • Across five years, Common Equity topped out at $4.3 million in Q2 2025 and bottomed at -$10.0 million in Q2 2023.
  • The 4-year median for Common Equity is -$2.5 million (2024), against an average of -$2.6 million.
  • The largest annual shift saw Common Equity plummeted 186.26% in 2023 before it skyrocketed 247.36% in 2024.
  • A 4-year view of Common Equity shows it stood at -$5.6 million in 2022, then surged by 74.82% to -$1.4 million in 2023, then surged by 247.36% to $2.1 million in 2024, then increased by 10.5% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for NRXS's Common Equity are $2.3 million (Q3 2025), $4.3 million (Q2 2025), and $258479.0 (Q1 2025).